Skip to main content

Advertisement

SpringerLink
Log in

Diagnosis and Treatment of Migraine: Recommendations of Russian Experts

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Recommendations for the diagnosis and treatment of migraine based on the principles of evidence-based medicine are presented. The latest edition of the International Classification of Migraine is provided. Diagnostic methods and criteria are oriented to discriminating different types of migraine. Recommendations are given on the basis of data on the epidemiology and pathophysiological mechanisms of migraine. The most effective medication-based and non-medication-based approaches to the management of migraine patients are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. “Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 GBD 2013 Mortality and Causes of Death Collaborators,” Lancet, 385, 117 (2015), doi: 10.1016/S0140-6736(14)61682-2.

  2. B. K. Rasmussen, R. Jensen, M. Schroll, and J. Olesen, “Epidemiology of headache in a general population – a prevalence study,” J. Clin. Epidemiol., 44, 1147–1157 (1991), doi: https://doi.org/10.1016/0895-4356(91) 90147-2.

  3. I. Ayzenberg, Z. Katsarava, A. Sborowski, et al., “The prevalence of primary headache disorders in Russia: A countrywide survey,” Cephalalgia, 32, No. 5, 373–381 (2012), doi: https://doi.org/10.1177/033310241 2438977.

  4. E. R. Lebedeva, N. R. Kobzeva, D. Gilev, and J. Olesen, “Prevalence of primary headache disorders diagnosed according to ICHD-3 beta in three different social groups,” Cephalalgia, 36, No. 6, 579–588 (2015), doi: https://doi.org/10.1177/0333102415596442.

    Article  PubMed  Google Scholar 

  5. G. T. Glembotskaya and O. V. Kozub, “Pharmacoeconomic assessment of the ‘burden’ of migraine in the Russian Federation,” Klin. Farmakol. Ter., 22, No. 2, 83–86 (2013).

    Google Scholar 

  6. E. V. Maksyukova and V. V. Osipova, “Migraine in elderly patients: a clinical psychological analysis,” Ross. Zh. Boli, No. 2, 33 (2011).

  7. V. V. Osipova, E. Snopkova, and G. A. Tabeeva, “Migraine in the elderly,” in: Case-Based Diagnosis and Management of Headache Disorder. Headache, A. Siva and C. Lampl (eds.), P. Marteletti and R. Jensen (Ser. eds.), Springer International Publishing (2015), pp. 109–118, doi: https://doi.org/10.1007/978-3-319-06886-2_16.

  8. A. C. Lyngberg, B. K. Rasmussen, T. Jorgensen, and R. Jensen, “Has the prevalence of migraine and tension-type headache changed over a 12-year period? A Danish population survey,” Eur. J. Epidemiol., 20, No. 3, 243–249 (2005), doi: https://doi.org/10.1007/s10654-004-6519-2.

    Article  PubMed  Google Scholar 

  9. E. V. Snopkova, A. V. Sergeev, V. V. Osipova, “Comparative clinical psychological analysis of migraine in young and elderly patients,” Nevrol. Zh., 17, No. 6, 32–37 (2012), doi: 10.18821/1560-9545-2012-17-6-32-37.

  10. “The International Classification of Headache Disorders, 3rd edition (beta version),” Cephalalgia, 33, No. 9, 629–808 (2013), doi: https://doi.org/10.1177/0333102413485658.

  11. A. M. Vein, O. A. Kolosova, N. A. Yakovlev, and T. A. Slyusar’, Migraine, Moscow (1995).

  12. G. R. Tabeeva and N. N. Yakhno, Migraine, GEOTAR-Media, Moscow (2011).

  13. A. V. Sergeev, M. I. Meshcherina, and G. R. Tabeeva, “Analgesic overuse headache: clinical psychological and neurophysiological analysis, characteristics of the withdrawal period,” Epileps. Paroks. Sost., 3, No. 3, 21–28 (2011).

    Google Scholar 

  14. H.-C. Diener, V. Limmroth, and Z. P. J. Katsarava, “Medical-overuse headache,” in: Chronic Daily Headache for Clinicians, P. J. Goadsby and D. W. Dodick (eds.), Decker, Hamilton (2005).

  15. M. Obermann and Z. Katsarava, “Management of medication over-use headache,” Exp. Rev. Neurother., 7, No. 9, 1145–1155 (2007), doi: https://doi.org/10.1586/14737175.7.9.1145.

    Article  CAS  Google Scholar 

  16. Z. Katsarava and I. V. Aizenberg, “Medication-induced headache,” in: Proc. All-Russ. Sci. Appl. Conf. Headache 2007, Moscow (2007), pp. 80–91.

  17. A. R. Artemenko, Chronic Migraine: Clinical Features, Pathogenesis, Treatment: Dissert. Doct. Med. Sci., Moscow (2010).

  18. A. V. Amelin, Yu. N. Bogdanova, M. I. Koreshkina, et al., “Diagnosis of primary and symptomatic forms of chronic daily headache,” Zh. Nevrol. Psikhiat., 111, No. 4, 69–71 (2011).

    Google Scholar 

  19. O. V. Kurushina, V. A. Urvachev, and L. A. Ivashneva, “The role of psychoemotional characteristics of patients in the formation of primary cephalalgias,” Vestn. Pyatigorsk. Gos. Lingvist. Univ., 2, 332–333 (2010).

    Google Scholar 

  20. S. A. Gromova and G. R. Tabeeva, “Menstrual migraine: epidemiology and pathogenesis,” Zh. Nevrol. Psikhiat.. 111, No. 7, 44–48 (2011).

    Google Scholar 

  21. V. Osipova, I. Ayzenberg, A. Amelin, et al., “The highest prevalence of CDH in Russia: why?” Cephalalgia, 35, No. 6, 287 (2015), doi: https://doi.org/10.1177/0333102415581304.

  22. J. Olesen, P. J. Goadsby, N. M. Ramadan, et al. (eds.), The Headaches, Lippincott Williams & Wilkins, Philadelphia (2006), 3rd ed.

  23. H. Massiou and A. J. MacGregor, “Influence of female hormones on migraines,” in: The Headaches, J. Olesen, P. J. Goadsby, N. Ramadan, et al. (eds.), Lippincott Williams & Wilkins, Philadelphia (2005), 3rd ed., pp. 331–342.

  24. E. R. Lebedeva, N. R. Kobzeva, D. V. Gilev, and E. Olesen, “Factors linked with the development of migraine and tension headache in three social groups,” Ural. Med. Zh., No. 2, 5–14 (2015).

  25. V. V. Osipova, A. P. Rachin, and Ya. B. Yudel’son, “Migraine: from correct diagnosis to appropriate treatment,” Sprav. Poliklin. Vracha, No. 1, 51–56 (2007).

  26. V. V. Osipova and G. R. Tabeeva, Primary Headache: Diagnosis, Clinical Features, Treatment. Practical Guidelines, Medical Information Agency Press, Moscow (2014).

  27. V. Osipova, R. Jensen, and C. Tassorelli, “The use of diaries in the management of headache,” in: Handbook of Headache (practical management), P. Martelletti, and T. J. Steiner (eds.) (2011), Vol. 4, pp. 197–209, doi: https://doi.org/10.1007/978-88-470-1700-9_13.

  28. G. R. Tabeeva, Prophylaxis of Migraine, Pulse (2007).

  29. Yu. E. Azimova, A. V. Sergeev, V. V. Osipova, and G. R. Tabeeva, “Diagnosis of treatment of headache in Russia: results from a questionnaire of physicians, “ Ross. Zh. Boli, No. 3–4, 12–17 (2010).

  30. A. R. Artemenko, A. L. Kurenkov, and K. V. Belomestova, “Principles of history-taking in the diagnosis of chronic migraine, “ Zh. Nevrol. Psikhiat., No. 9, 81–87 (2014).

  31. V. V. Osipova and T. G. Voznesenskaya, “Comorbidity of migraine: review of the literature and approaches to investigation,” Zh. Nevrol. Psikhiat. 107, No. 3, 64–73 (2007).

    CAS  Google Scholar 

  32. A. R. Artemenko and A. L. Kurenkov, Chronic Migraine, M.: ID ABV-Press, Moscow (2012).

  33. S. D. Silberstein, R. B. Lipton, and P. J. Goadsby, Headache in Clinical Practice, Martin Dunitz, London (2002), 2nd ed.

  34. T. J. Steiner, E. A. MacGregor, and D. T. G. Davies, Guidelines for All Healthcare Professionals in the Diagnosis and Management of Migraine, Tension-Type, Cluster and Medication Overuse Headache, British Association for the Study of Headache (2007), 3rd ed., pp. 1–523 (2007).

  35. M. I. Koreshkina, “Contemporary neuroimaging methods and the prophylactic treatment of migraine,” Zh. Nevrol. Psikhiat. 111, No. 9, 25–31 (2011).

    CAS  Google Scholar 

  36. M. I. Koreshkina, V. V. Osipova, T. N. Trofimova, et al., “The role of MRI in the diagnostic algorithms for migraine and the changes detected,” Ural. Med. Zh., No. 1, 25–32 (2013).

  37. R. W. Evans, “Diagnostic testing for headaches,” Med. Clin. N. Am., 85, No. 4, 865–885 (2001), doi: https://doi.org/10.1016/s0025-7125(05)70348-5.

    Article  PubMed  CAS  Google Scholar 

  38. M. E. Detsky, D. R. McDonald, M. O. Baerlocher, et al., “Does this patient with headache have a migraine or need neuroimaging?” JAMA, 296, 1274–1283 (2006), doi: https://doi.org/10.1001/jama.296.10.1274.

    Article  PubMed  CAS  Google Scholar 

  39. R. B. Lipton and M. E. Bigal, “Differential diagnosis of primary headaches. An algorithm based approach,” in: Migraine and Other Headache Disorders, R. B. Lipton and M. E. Bigal (eds.), Informa Healthcare, New York (2006), pp. 145–154.

  40. M. I. Koreshkina, A. D. Khalikov, Yu. V. Nazinkina, et al., “Studies of brain blood flow by high-field MRI perfusion during episodes of migraine with aura,” Epileps. Paroks. Sost., 4, No. 4, 12–17 (2012).

    Google Scholar 

  41. M. C. Kruit, M. A. van Buchem, L. J. Launer, et al., “Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: The population-based MRI CAMERA study,” Cephalalgia, 30, 129–136 (2010), doi: https://doi.org/10.1111/j.1468-2982.2009.01904.x.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. M. I. Koreshkina, S. W. Atlas, A. D. Khalikov, and E. A. Kosmacheva, “Magnetic resonance investigation 3.0 T detects white matter lesions of brain in case of chronic migraine,” Cephalalgia, 29, 127 (2009).

    Google Scholar 

  43. M. Ashina, J. M. Hansen, and J. Olesen, “Pearls and pitfalls in human pharmacological models of migraine: 30 years’ experience,” Cephalalgia, 33, No. 8, 540–553 (2013), doi: https://doi.org/10.1177/0333102412 475234.

  44. E. I. Guseva and A. B. Gekht (eds.), Brain Diseases – Medical and Social Aspects, Buki-Vedi, Moscow (2016).

  45. V. V. Osipova, Yu. E. Azimova, G. R. Tabeeva, et al., “Diagnosis of headaches in Russia and countries in the post-Soviet sphere of influence: current state of the problem and ways to solve it,” Ann. Klin. Eksperim. Nevrol., 6, No. 2, 16–21 (2012).

    Google Scholar 

  46. E. R. Lebedeva, N. R. Kobzeva, D. V. Gilev, and E. Olesen, “Analysis of the quality of the diagnosis and treatment of primary headache in different social groups in the Urals region,” Nevrol. Neiropsikh. Psikhosom., No. 1, 19–26 (2015), doi: https://doi.org/10.14412/2074-2711-2015-1-19-26.

  47. R. W. Evans, “The neurological history and examination,” in: Saunders Manual of Neurological Practice, R. W. Evans (ed.), W. B. Sa unders, Philadelphia (2003), pp. 1–10.

  48. T. J. Steiner et al., European Principles of Management of Common Headache Disorders in Primary Care. Practical Guidelines for Doctors [Russian translation], V. V. Osipova, T. G. Voznesenskii, and G. R. Tabeeva (eds.), OGGI. A Promotional Product, Moscow (2010).

  49. S. D. Silberstein, “A new frontier for headache,” Front. Neurol., No. 1, 135 (2010), doi: https://doi.org/10.3389/fneur.2010.00135.

  50. A. V. Amelin, Yu. D. Ignatov, A. A. Skoromets, and A. Yu. Sokolov, Migraine (pathogenesis, clinical aspects, treatment), MEDpress, Moscow (2011).

  51. N. N. Yakhno, V. A. Parfenov, and V. V. Alekseev, Headache, Remedium, Moscow (2000).

  52. A. B. Danilov and Al. B. Danilov, Guidelines for Doctors with Different Specialties. The Control of Pain: A Biosocial Approach, AMM PRESS, Moscow (2014).

  53. J. Olesen, M. G. Bousser, H.-C. Diener, et al., “New appendix criteria open for a broader concept of chronic migraine,” Cephalalgia, 26, 742–746 (2006), doi: https://doi.org/10.1111/j.1468-2982.2006.01172.x.

    Article  PubMed  CAS  Google Scholar 

  54. G. R. Tabeeva, Yu. E. Azimova, and M. I. Margulis, “Refractory migraine: from pathogenesis to rational treatment,” Russ. Med. Zh., No. 1, 18–19 (2011).

  55. A. Ferrari, “Headache: one of the most common and troublesome adverse reactions to drugs,” Curr. Drug Saf., 1, No. 1, 43–58 (2006), doi: https://doi.org/10.2174/157488606775252610.

    Article  PubMed  CAS  Google Scholar 

  56. A. Ferrari, L. Spaccapelo, and E. Sternieri, “Pharmacoepidemiology of triptans in a headache centre,” Cephalalgia, 30, No. 7, 847–854 (2010), doi: https://doi.org/10.1177/0333102409357956.

    Article  PubMed  Google Scholar 

  57. Z. Katsarava, D. C. Buse, A. N. Manack, and R. B. Lipton, “Defining the differences between episodic migraine and chronic migraine,” Curr. Pain Headache Rep., 16, No. 1, 86–92 (2012), doi: https://doi.org/10.1007/s11916-011-0233-z.

    Article  PubMed  Google Scholar 

  58. M. Maizels, “Clonazepam for refractory headache: three cases illustrative of benefit and risk,” Headache, 50, No. 4, 650–656 (2010), doi: https://doi.org/10.1111/j.1526-4610.2010.01633.x.

    Article  PubMed  Google Scholar 

  59. M. I. Koreshkina, “Epidemiology, pathogenetic mechanisms, diagnosis, and treatment of migraine. The practicing doctor today,” Zh. Poslediplom. Obraz., No. 3, 2–13 (2015).

  60. E. V. Ekusheva and I. V. Damulin, “Current approaches to the treatment of refractory migraine,” Ross. Med. Zh., No. 5, 45–52 (2014).

  61. T. J. Steiner, The Reform of Headache Services: a First-Class Service in the ‘Modern and Dependable’ NHS (MSc thesis), University of London, London (2002).

  62. H.-C. Diener, C. Gaul, R. Jensen, et al., “Integrated headache care,” Cephalalgia, 31, No. 9, 1039–1047 (2011), doi: https://doi.org/10.1177/0333102411409075.

    Article  PubMed  Google Scholar 

  63. G. R. Tabeeva, “Features of migraine associated with the menstrual cycle,” Lech. Zabol. Nerv. Sist., 14, No. 2, 32–35 (2014).

    Google Scholar 

  64. A. V. Amelin, Current Aspects of the Diagnosis, Pathogenesis, and Treatment of Migraine, NTTs AMOUNT, Moscow (2007).

  65. A. V. Amelin, “Non-steroidal anti-inflammatories in migraine,” Lech. Vrach, No. 5, 25–27 (2012).

  66. E. G. Filatova, “Treatment of migraine attacks,” Russ. Med. Zh., 21, No. 16, 862–865 (2013).

    Google Scholar 

  67. E. G. Filatova, A. V. Amelin, G. R. Tabeeva, et al., “Ready – the first Russian multicenter study of the efficacy of Relpax (eletriptan) in the treatment of migraine,” Lech. Nerv. Bolezn., No. 2, 19–22 (2006).

  68. E. V. Ekusheva and I. V. Damulin, “Refractory migraine: current methods of drug therapy,” Nevrol. Vestn. im. Bekhtereva, XLVI, No. 4, 44–52 (2014).

  69. N. N. Yakhno and M. L. Kukushkin (eds.), Pain: Practical Guidelines for Doctors, Russian Academy of Medical Sciences Press, Moscow (2011).

  70. W. J. Becker, M. Gawel, G. Mackie, et al., “Migraine treatment,” Can. J. Neurol. Sci., 34, 10–19.35 (2007).

  71. N. V. Latysheva “Current rules for the treatment of migraine attacks – avoiding the stereotype,” Lech. Zabol. Nerv. Sist., 2, No. 7, 21–27 (2011).

    Google Scholar 

  72. “Approval of standard primary medical-sanitary care in migraine (differential diagnosis and treatment of attacks),” Decree of the Ministry of Health of the Russian Federation No. 1550n of December 24, 2012. Treatment of Attacks (analgesics, triptans, and xefocam).

  73. V. V. Osipova, “Migraine and tension headache. V. Clinical recommendations,” in: Neurology and Neurosurgery, E. I. Gusev and A. N. Konovalov (eds.), GEOTAR-Media, Moscow (2015), 2nd ed.

  74. S. Evers, J. Afra, A. Frese, et al., “EFNS guideline on the drug treatment of migraine – report of an EFNS task force,” Eur. J. Neurol., 16, No. 9, 968–981 (2009), doi: https://doi.org/10.1111/j.1468-1331.2009.02748.x.

    Article  PubMed  CAS  Google Scholar 

  75. E. V. Ekusheva and I. V. Damulin, “Current approaches to the treatment of migraine during pregnancy,” Zh. Nevrol. Psikhiat., 115, No. 11, 86–94 (2015), doi: https://doi.org/10.17116/jnevro2015115111124-132.

    Article  Google Scholar 

  76. A. M. Vein, T. V. Pukhal’skaya, V. V. Osipova, and O. A. Kolosova, “Sumatriptan. 11 years of use in the clinic,” Lech. Nerv. Bolezn., 3, No. 2, 18–21 (2002).

    Google Scholar 

  77. V. V. Osipova, “Antimigraine agents,” Guidelines for the Rational Use of Drugs (a formulary), A. G. Chuchalin et al. (eds.), GEOTAR-Media, Moscow (2006).

  78. “Canadian Headache Society guideline for migraine prophylaxis,”Can. J. Neurol. Sci., 39, No. 2, 1–63 (2012), doi: https://doi.org/10.1017/s0317167100015109.

  79. I. Worthington, T. Pringsheim, M. J. Gawel, et al., Canadian Headache Society Acute Migraine Treatment Guideline Development Group, “Canadian Headache Society Guideline: Acute Drug Therapy for Migraine Headache,” Can. J. Neurol. Sci., 40, No. 3, 1–80 (2013), doi: https://doi.org/10.1017/s0317167100017819.

  80. European Headache Federation. EHF Missions, www.ehf-org.org/mission.asp.

  81. L. Bendtsen, S. Birk, H. Kasch, et al., “Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition, 2012,” J. Headache Pain, 13, No. 1, 1–29 (2012), doi: https://doi.org/10.1007/s10194-011-0402-9.

    Article  PubMed Central  Google Scholar 

  82. T. R. Smith, A. Sunshine, S. R. Stark, et al., “Sumatriptan and naproxen sodium for the acute treatment of migraine,” Headache, 45, 983–991 (2005), doi: https://doi.org/10.1111/j.1526-4610.2005.05178.x.

    Article  PubMed  Google Scholar 

  83. A. B. Danilov, I. G. Podymova, E. G. Filatova, et al., “Treatment of migraine attacks: effi cacy and safety,” Med. Konsilium, 15, No. 2, 19–22 (2013).

    Google Scholar 

  84. Yu. E. Azimova and A. P. Rachin, “Migraine, caffeine, ergotamine: the classical trio,” Poliklinika, No. 1, 28–30 (2016).

  85. N. V. Latysheva and E. G. Filatova, “Venlafaxine (Velafax) in the treatment of chronic daily headache: mechanism of action,” Lech. Zabol. Nerv. Sist., No. 2, 24–27 (2010).

  86. A. R. Artemenko, A. L. Kurenkov, and K. V. Belomestova, “Classification, diagnosis, and treatment of chronic migraine: review of new data,” Zh. Nevrol. Psikhiat., 11, 91–96 (2013).

    Google Scholar 

  87. G. H. Guyatt, A. D. Oxman, G. E. Vist, et al., “GRADE: an emerging consensus on rating quality of evidence and strength of recommendations,” BMJ, 336, 924–926 (2008), doi: https://doi.org/10.1136/bmj.39489.470347.

    Article  PubMed  PubMed Central  Google Scholar 

  88. E. Tronvik, L. J. Stovner, G. Helde, et al., “Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial,” JAMA, 289, 65–69 (2003), doi: https://doi.org/10.1001/jama.289.1.65.

    Article  PubMed  CAS  Google Scholar 

  89. S. Evers and R. Jensen “Treatment of medication overuse headache – guideline of the EFNS headache panel, European Federation of Neurological Societies,” Eur. J. Neurol., 18, No. 9, 1115–1121 (2011), doi: https://doi.org/10.1111/j.1468-1331.2011.03497.x.

  90. S. Evers, “Treatment of migraine with prophylactic drugs,” Expert Opin. Pharmacother., 9, No. 15, 2565–2573 (2008), doi: https://doi.org/10.1517/14656560802377046.

    Article  PubMed  CAS  Google Scholar 

  91. S. Silberstein, P. Tfelt-Hansen, D. W. Dodick, et al., “Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults,” Cephalalgia, 28, 484–495 (2008), doi: https://doi.org/10.1111/j.1468-2982.2008.01555.x.

    Article  PubMed  CAS  Google Scholar 

  92. A. R. Artemenko, A. L. Kurenkov, and O. S. Antipova, Diagnosis and Treatment of Chronic Migraine, Gor. Liniya – Telekom, Moscow (2014).

  93. M. V. Naprienko, N. V. Latysheva, and E. G. Filatova, “New potentials in the treatment of chronic daily headache,” Zh. Nevrol. Psikhiat., 110, No. 1, 49–54 (2010).

    Google Scholar 

  94. S. D. Silberstein, R. B. Lipton, D. W. Dodick, et al., “Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial,” Headache, 47, 170–180 (2007), doi: https://doi.org/10.1111/j.1526-4610.2006.00684.x.

    Article  PubMed  Google Scholar 

  95. P. A. Kowacs, E. J. Piovesan, and S. J. Tepper, “Rejection and acceptance of possible side effects of migraine prophylactic drugs,” Headache, 49, 1022–1027 (2009), doi: https://doi.org/10.1111/j.1526-4610.2009.01431.x.

    Article  PubMed  Google Scholar 

  96. M. Peters, C. Jenkinson, S. Perera, et al., “Quality in the provision of headache care. 2: Defining quality and its indicators,” J. Headache Pain, 13, 449–457 (2012), doi: https://doi.org/10.1007/s10194-012-0465-2.

    Article  PubMed  PubMed Central  Google Scholar 

  97. F. G. Freitag, S. D. Collins, H. A. Carlson, et al., Migraine Study Group, “A randomized trial of divalproex sodium extended release tablets in migraine prophylaxis,” Neurology, 58, 1652–1659 (2002), doi: https://doi.org/10.1212/wnl.58.11.1652.

  98. G. Bussone, H. C. Diener, J. Pfeil, and S. Schwalen, “Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials,” Int. J. Clin. Pract., 59, 961–968 (2005), doi: https://doi.org/10.1111/j.1368-5031.2005.00612.x.

    Article  PubMed  CAS  Google Scholar 

  99. H. C. Diener, G. Bussone, J. C. Van Oene, et al., and TOPMAT-MIG-201(TOP-CHROME) Study Group,”Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study,” Cephalalgia, 27, No. 7, 814–823 (2007), doi: https://doi.org/10.1111/j.1468-2982.2007.01326.x.

  100. P. S. Sorensen, B. H. Larsen, M. J. Rasmussen, et al., “Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability,” Headache, 31, 650–657 (1991), doi: https://doi.org/10.1111/j.1526-610.1991.hed3110650.x.

    Article  PubMed  CAS  Google Scholar 

  101. N. V. Latysheva, E. G. Filatova, G. R. Tabeeva, et al., “Practical questions in the management of patients with chronic migraine. Recommendations of Russian experts,” Nervno-Mysh. Bol., 5, No. 3, 2–7 (2015), doi: https://doi.org/10.17650/2222-8721-2015-5-3-31-36.

  102. Y. Nestoriuc, A. Martin, W. Rief, and F. Andrasik, “Biofeedback treatment for headache disorders: a comprehensive efficacy review,” Appl. Psychophysiol. Biofeedback, 33, 125–140 (2008), doi: https://doi.org/10.1007/s10484-008-9060-3.

    Article  PubMed  Google Scholar 

  103. M. V. Naprienko, “Acupuncture in the restorative treatment of patients with chronic migraine and chronic tension headache,” Manual. Terapiya, 3, No. 39, 64–69 (2010).

    Google Scholar 

  104. V. A. Golovacheva and V. A. Parfenov “Cognitive behavioral therapy in the treatment of patients with migraine,” Nevrol. Zh., 3, No. 20, 37–43 (2015), doi: https://doi.org/10.18821/1560-9545-2015-20-3-37-43.

  105. V. Golovacheva, V. Parfenov, G. Tabeeva, and V. S. Osipova, “Combined cognitive behavioral and pharmacological therapies for chronic migraine and chronic tension-type headache: are treatment responses different?” Cephalalgia, 35, No. 6, 272 (2015), doi: https://doi.org/10.1177/0333102415581304.

  106. S. Zhu and M. J. Marmura, “Non-invasive neuromodulation for headache disorders,” Curr. Neurol. Neurosci. Rep., 16, No. 2, 11 (2016), doi: https://doi.org/10.1007/s11910-015-0620-7.

    Article  PubMed  Google Scholar 

  107. J. Shoenen, M. Allena, and D. G. Magis, “Neurostimulation therapy in intractable headaches,” in: Handbook of Clinical Neurology. Headache, G. Nappi and M. A. Moskowitz (eds.), Elsevier B. V. (2011), Vol. 97 (3rd ser.), pp. 443–450.

  108. S. K. Aurora, D. W. Dodick, C. C. Turkel, et al., PREEMPT 1 Chronic Migraine Study Group, “OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebocontrolled phase of the PREEMPT 1 trial,” Cephalalgia, 30, No. 7, 793–803 (2010), doi: https://doi.org/10.1111/j.1526-4610.2011.01898_2.x.

  109. A. Negro, M. Curto, L. Lionetto, and P. Martelletti, “A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience,” J. Headache Pain, 17, No. 1, 1 (2015), doi: https://doi.org/10.1186/s10194-016-0591-3.

    Article  PubMed  Google Scholar 

  110. A. R. Artemenko, A. L. Kurenkov, and K. V. Belomestova, “The question of the lack of substitutability drugs of the botulinum toxin type,” Med. Sovet, 5, 112–123 (2015).

    Google Scholar 

  111. A. Blumenfeld, S. D. Silberstein, D. W. Dodick, et al., “Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program,” J. Headache Pain, 50, No. 9, 1406–1418 (2010), doi: https://doi.org/10.1111/j.1526-4610.2010.01766.x.

    Article  Google Scholar 

  112. A. Negro, M. Curto, L. Lionetto, et al., “OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study,” Springer Plus, 4, 826 (2015), doi: https://doi.org/10.1186/s40064-015-1636-9.

  113. E. G. Filatova, “Overuse headache,” in: New Progress in the Treatment and Diagnosis of Headache: 4th Ann. Conf. Vein Discussions 2008, www.paininfo.ru/events/veinconference/1321.html.

  114. Z. Katsarava and R. Jensen, “Medication-overuse headache: where are we now?” Curr. Opin. Neurol., 20, No. 3, 326–330 (2007), doi: https://doi.org/10.1097/wco.0b013e328136c21c.

    Article  PubMed  Google Scholar 

  115. K. Rabe, L. Pageler, C. Gaul, et al., “Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study,” Cephalalgia, 33, No. 3, 202–207 (2013), doi: https://doi.org/10.1177/0333102412462638.

    Article  PubMed  Google Scholar 

  116. K. Hagen, M. Linde, T. J. Steiner, et al., “Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trondelag Health Studies,” Pain, 153, No. 1, 56–61 (2012), doi: https://doi.org/10.1016/j.pain.2011.08.018.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology Research Department, Research Center, Sechenov First Moscow State Medical University, Russian Ministry of Health, Moscow, Russia

    V. V. Osipova, A. R. Artemenko, A. V. Sergeev & N. N. Yakhno

  2. Scientific and Applied Psychoneurology Center, Moscow Department of Health, Moscow, Russia

    V. V. Osipova & A. B. Gekht

  3. Department of Nervous Diseases, Institute of Professional Education, Sechenov First Moscow State Medical University, Russian Ministry of Health, Moscow, Russia

    E. G. Filatova, N. V. Latysheva & Al. B. Danilov

  4. Aleksandr Vein Headache and Autonomic Diseases Clinic, Moscow, Russia

    E. G. Filatova, N. V. Latysheva, E. V. Ekusheva & M. V. Naprienko

  5. Department of Neurology and Neurosurgery and Department of Emergency Medicine, Urals State Medical University, Russian Ministry of Health, Ekaterinburg, Russia

    E. R. Lebedeva

  6. Europe–Asia Headache Treatment Center, Ekaterinburg, Russia

    E. R. Lebedeva

  7. University Headache Clinic, Moscow, Russia

    Yu. E. Azimova & K. V. Skorobogatykh

  8. Department of Neurology, Pavlov First St. Petersburg Medical University, St. Petersburg, Russia

    A. V. Amelin

  9. Headache Treatment Center, Scandinavia Clinic, AVA-PETER Company, St. Petersburg, Russia

    M. I. Koreshkina

  10. Department of Integrative Medicine, Sechenov First Moscow State Medical University, Russian Ministry of Health, Moscow, Russia

    M. V. Naprienko

  11. Burdenko National Scientific and Applied Neurology Center, Russian Ministry of Health, Moscow, Russia

    E. D. Isagulyan

  12. Department of Neurology, Russian Science Center for Rehabilitation and Balneology, Russian Ministry of Health, Moscow, Russia

    A. P. Rachin

  13. Department of Neurology and Neurosurgery with Medical Genetics, Neurology, Manual Therapy, and Reflex Therapy, Faculty of Advanced Physicians, Volgograd State Medical University, Russian Ministry of Health, Volgograd, Russia

    O. V. Kurushina

  14. Department of Neurology and Neurosurgery, Faculty of Therapy, Sechenov First Moscow State Medical University, Russian Ministry of Health, Moscow, Russia

    V. A. Parfenov & G. R. Tabeeva

  15. Department of Neurology, Neurosurgery, and Medical Genetics, Pirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia

    A. B. Gekht

Authors
  1. V. V. Osipova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. G. Filatova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. R. Artemenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. R. Lebedeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu. E. Azimova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. V. Latysheva
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. V. Sergeev
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. V. Amelin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. I. Koreshkina
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K. V. Skorobogatykh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E. V. Ekusheva
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M. V. Naprienko
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E. D. Isagulyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A. P. Rachin
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Al. B. Danilov
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. O. V. Kurushina
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. V. A. Parfenov
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. G. R. Tabeeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. A. B. Gekht
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. N. N. Yakhno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. V. Osipova.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 117, No. 1, Iss. 2, For the Practicing Doctor, pp. 28–42, January, 2017.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Osipova, V.V., Filatova, E.G., Artemenko, A.R. et al. Diagnosis and Treatment of Migraine: Recommendations of Russian Experts. Neurosci Behav Physi 48, 621–635 (2018). https://doi.org/10.1007/s11055-018-0608-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-018-0608-2

Keywords

Search

Navigation